Skip to main content

Table 2 Clinician-Reported Participant Characteristics

From: The content validity of the PSS in patients with plaque psoriasis

  Total Sample (N = 20)
Time Since Psoriasis Diagnosis, years
 Mean ± SD 17.9 ± 9.9
 Median (IQR) 19.6 (11.1–24.1)
 Range (Min – Max) (0.2–38.6)
Time on Systemic Treatment, years
 Mean ± SD 4.4 ± 4.8
 Median (IQR) 2.3 (1.4–7.0)
 Range (Min – Max) (0.1–20.0)
Comorbidities, n (%)
 Anxiety 2 (10%)
 Depression 2 (10%)
 Psoriatic Arthritis 4 (20%)
 Othera 12 (60%)
 No other health conditions 8 (40%)
Current treatmentsb, n (%)
 Secukinumab 1 (5%)
 Etanercept 3 (15%)
 Folic Acid 1 (5%)
 Adalimumab 4 (20%)
 Ixekizumab 4 (20%)
 Methotrexate 1 (5%)
 Ustekinumab 5 (25%)
 Ultraviolet B (shortwave) Waves (UVB) 2 (10%)
 Other 1 (5%)
  1. aNot mutually exclusive; other comorbidities included: atrial fibrillation, diabetes [6], hyperlipidemia [2], hypertension [5], obesity [2], restless legs, hypothyroidism, post-menopausal, peripheral edema.
  2. bNot mutually exclusive